Age-Related Macular Degeneration Market Segmental Analysis by Therapeutics, Diagnostics, Patent, Drugs Policy and Regulatory Landscape


The market is experiencing growth due to the rising geriatric population, growing pipeline for AMD therapeutics, surging chronic disease prevalence, and increasing healthcare expenditure. Age-related macular degeneration is a retinal disorder, which is indicated by changes in the fundus of the eye. It commonly affects the elderly, in which, first, the central vision becomes blurred, which ultimately leads to blindness.
The age-related macular degeneration market is classified into Asia-Pacific, Europe, North America, and Rest of the World, based on region. In 2015, the highest value share in the market was held by the North American region. This was attributed to the rising prevalence of conditions, such as obesity and hypertension. Further, the presence of major pharmaceutical companies supports the regional market growth. In 2022, with high healthcare expenditure of countries in the region, it is predicted to hold more than 90.0% of the market share.
Download Report Sample at:
The age-related macular degeneration market is growing due to the rising geriatric population. Old age is one of the major risk factors of the disease, which may lead to visual impairment, and eventually complete blindness. A report on global aging population was published by the United Nations Department of Economic and Social Affairs, which mentioned that the global population of people in the 60 and above age group, is growing at a high rate. The share of geriatric population by 2050 is predicted to grow to 21.1% from 11.7% in 2013.

Therefore, the market for AMD is predicted to register remarkable growth in the forecast period with the rising prevalence of this disease and surging geriatric population.

Share:

No comments:

Post a Comment

Popular Posts

Blog Archive